Chemomab Therapeutics (NASDAQ:CMMB) Ltd. is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of antibody‐based therapies for the treatment of solid tumors. The company’s proprietary platform centers on targeting tumor-associated carbohydrate antigens, a class of glycoproteins that are overexpressed in many aggressive cancers but rarely found on healthy cells. By engineering monoclonal antibodies that precisely bind these glycan markers, Chemomab aims to deliver potent anti‐tumor activity with minimized off‐target effects.
The company’s lead candidate, CMMB118, is an anti-Tn antigen antibody currently in Phase I/II clinical trials for multiple advanced solid tumor indications, including colorectal and ovarian cancers. In addition to CMMB118, Chemomab maintains a diversified pipeline of preclinical programs focused on novel carbohydrate targets such as sialyl‐LewisX and Globo H. These programs leverage the company’s antibody engineering expertise and are designed to improve tumor penetration and immune system recruitment.
Founded in 2014 as a spin-out from a leading academic research institute in Israel, Chemomab has established R&D operations in Tel Aviv and a U.S. research facility in Cambridge, Massachusetts. The company’s global footprint supports collaborative efforts with clinical sites across North America, Europe and Asia, enabling multi‐center studies and facilitating regulatory engagement in key markets. Chemomab’s strategic partnerships with academic cancer centers and specialty CROs bolster its ability to advance candidates efficiently through the clinic.
Chemomab’s leadership team brings together seasoned professionals in oncology drug development. Ariel Hertz, Ph.D., serves as Chief Executive Officer, drawing on more than 15 years of experience in antibody discovery and clinical development. The board of directors and scientific advisory board include experts in immuno-oncology, glycobiology and translational medicine, providing strategic guidance as the company progresses its pipeline. Together, the team is committed to delivering innovative therapies that address significant unmet needs in cancer treatment.
